KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Elanco Animal Health (ELAN) Research & Development (2017 - 2025)

Elanco Animal Health (ELAN) has disclosed Research & Development for 9 consecutive years, with $93.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 14.81% to $93.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $368.0 million through Dec 2025, up 6.98% year-over-year, with the annual reading at $368.0 million for FY2025, 6.98% up from the prior year.
  • Research & Development hit $93.0 million in Q4 2025 for Elanco Animal Health, up from $89.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $94.0 million in Q2 2021 to a low of $78.0 million in Q3 2022.
  • Historically, Research & Development has averaged $86.4 million across 5 years, with a median of $87.0 million in 2024.
  • Biggest YoY gain for Research & Development was 59.32% in 2021; the steepest drop was 20.0% in 2021.
  • Year by year, Research & Development stood at $92.0 million in 2021, then dropped by 13.04% to $80.0 million in 2022, then fell by 1.25% to $79.0 million in 2023, then grew by 2.53% to $81.0 million in 2024, then increased by 14.81% to $93.0 million in 2025.
  • Business Quant data shows Research & Development for ELAN at $93.0 million in Q4 2025, $89.0 million in Q3 2025, and $92.0 million in Q2 2025.